Sign in

Private company

ANTARES PHARMA, INC.

American surgical and medical instruments and apparatus company based in Ewing2

In its 2022 annual report the company says: “We develop, manufacture and commercialize, for ourselves or with partners, novel therapeutic products using our advanced drug delivery systems that are designed to provide commercial or functional advantages such as improved safety and efficacy, convenience, improved tolerability, and enhanced patient comfort and adherence. We have a portfolio of proprietary and partnered commercial products and ongoing product development programs in various stages of development.”56

Last updated Oct 21, 2026.

Overview

  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersEwing, United States2
  • Incorporated inDE3
  • Business address100 Princeton South, Suite 300, Ewing, Nj 086283
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI5299004QMIHMZUUNYY442
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 39626252

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

35.8%Operating margin4
25.2%Net margin4
23.0%Revenue growth, 20214
26.3%Return on equity4
0.10×Debt to equity4
$30.0MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development8¢$14.5M
  • Selling, general and admin40¢$73.9M
  • Other costs16¢$29.7M
  • Interest2¢$3.6M
  • Income tax9¢$16.0M
  • Profit25¢$46.3M

Out of $184.0M in revenue.4

Where each dollar of operating cash went, fiscal 2021

  • Capital spending18¢$6.6M
  • Kept or used elsewhere82¢$30.0M

Out of $36.6M of cash from operations.4

Financial statements

Revenue56784$184.0M in 2021+303% since 2015
0$50.0M$100.0M$150.0M$200.0M2015: $45.7M$45.7M20152016: $52.2M$52.2M2016+14%2017: $54.5M$54.5M2017+4%2018: $63.6M$63.6M2018+17%2019: $123.9M$123.9M2019+95%2020: $149.6M$149.6M2020+21%2021: $184.0M$184.0M2021+23%
Gross profit567$73.4M in 2019+180% since 2015
0$20.0M$40.0M$60.0M$80.0M2015: $26.2M$26.2M20152016: $23.4M$23.4M2016−11%2017: $27.0M$27.0M2017+16%2018: $32.5M$32.5M2018+20%2019: $73.4M$73.4M2019+126%
Operating income56784$65.9M in 2021
-$25.0M0$25.0M$50.0M$75.0M2015: -$20.5M-$20.5M20152016: -$24.1M-$24.1M2016+18%2017: -$15.6M-$15.6M2017−35%2018: -$4.1M-$4.1M2018−74%2019: $992.0K$992.0K20192020: $13.6M$13.6M2020+1273%2021: $65.9M$65.9M2021+384%
Net income56784$46.3M in 2021
-$25.0M0$25.0M$50.0M$75.0M2015: -$20.7M-$20.7M20152016: -$24.3M-$24.3M2016+18%2017: -$16.7M-$16.7M2017−31%2018: -$6.5M-$6.5M2018−61%2019: -$2.0M-$2.0M2019−69%2020: $56.2M$56.2M20202021: $46.3M$46.3M2021−18%
Fiscal year2015201620172018201920202021
Revenue$45.7M5$52.2M6$54.5M7$63.6M8$123.9M4$149.6M4$184.0M4
Cost of revenue$19.5M5$28.8M5$27.5M5$31.1M7$50.5M7
Gross profit$26.2M5$23.4M6$27.0M7$32.5M7$73.4M7
Research and development$19.7M5$19.6M6$11.9M7$12.3M8$10.6M4$10.1M4$14.5M4
Selling, general and admin$26.9M5$27.9M6$31.6M7$36.8M8$61.8M4$62.8M4$73.9M4
Operating expenses$156.6M4
Operating income-$20.5M5-$24.1M6-$15.6M7-$4.1M8$992.0K4$13.6M4$65.9M4
Interest$1.4M7$2.7M8$3.5M4$3.8M4$3.6M4
Income before tax$62.3M4
Income tax$175.0K5$100.0K6$04-$46.3M4$16.0M4
Net income-$20.7M5-$24.3M6-$16.7M7-$6.5M8-$2.0M4$56.2M4$46.3M4
Earnings per share-$0.048-$0.014$0.344$0.274
Earnings per share (diluted)-$0.048-$0.014$0.334$0.264
Shares (weighted, basic)169.2M shares4
Shares (weighted, diluted)174.7M shares4

Compare ANTARES PHARMA, INC. with another company

Corporate structure

ANTARES PHARMA, INC. is part of a group headed by Halozyme Therapeutics. 7 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ANTARES PHARMA, INC.

  • Halozyme Therapeutics San Diego, California, United States
    • ANTARES PHARMA, INC. Ewing, New Jersey, United States
    • Antares Pharma IPL AG Subsidiary · Switzerland
    • Elektrofi Security Corp. Subsidiary · Massachusetts, United States
    • Halozyme Hypercon, Inc. Subsidiary · Delaware, United States
    • Halozyme Surf Bio, Inc. Subsidiary · Delaware, United States
    • Halozyme, Inc. Subsidiary · California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ANTARES PHARMA, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$39.2M4 Dec 31, 2021$34.4M4 Dec 31, 2020+14.0%
Accumulated depreciation$13.2M4 Dec 31, 2021$10.4M4 Dec 31, 2020+27.1%
Property and equipment, net$26.0M4 Dec 31, 2021$24.0M4 Dec 31, 2020+8.3%
Operating-lease assets (leased space)$3.8M4 Dec 31, 2021$4.6M4 Dec 31, 2020−18.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$65.9M4 Dec 31, 2021$53.1M4 Dec 31, 2020+24.0%
Marketable securities, current$1.2M4 Dec 31, 2021$04 Dec 31, 2020

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.1M4 Dec 31, 2021$1.1M4 Dec 31, 20200%
Intangible assets, net (excluding goodwill)$17.9M4 Dec 31, 2021$7.7M4 Dec 31, 2020+132.4%
Finite-lived intangibles, gross$19.9M4 Dec 31, 2021$11.5M4 Dec 31, 2020+72.8%
Accumulated amortization$2.0M4 Dec 31, 2021$3.8M4 Dec 31, 2020−47.8%
Finite-lived intangibles, net$17.9M4 Dec 31, 2021$7.7M4 Dec 31, 2020+132.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$11.5M4 Dec 31, 2021$18.2M4 Dec 31, 2020−36.6%
Raw materials$325.0K4 Dec 31, 2021$325.0K4 Dec 31, 20200%
Work in process$6.8M4 Dec 31, 2021$7.1M4 Dec 31, 2020−4.7%
Finished goods$4.4M4 Dec 31, 2021$10.8M4 Dec 31, 2020−58.8%

Leadership

Who has led ANTARES PHARMA, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jack E. Stover2006–2008
  2. Paul K. Wotton2008–2014
  3. Eamonn P. Hobbs2014–2015
  4. Robert F. Apple2016–2022

President

  1. Jack E. Stover2006–2008
  2. Paul K. Wotton2008–2014
  3. Eamonn P. Hobbs2014–2015
  4. Robert F. Apple2016–2022

Chief financial officer

  1. Robert F. Apple2006–2014
  2. James E. Fickenscher2014–2016
  3. Keith E. Muckenhirn2016
  4. Fred M. Powell2016–2022

Chief operating officer

  1. Paul K. Wotton2008
  2. Robert F. Apple2015
2010201520202025
Board members and other officers (20)

Former names

  • ANTARES PHARMA INCMay 4, 2005 to May 15, 20083
  • ANTARES PHARMA INCMay 20, 2002 to Jan 10, 20063
  • ANTARES PHARMA INC /MN/Aug 14, 2001 to May 14, 20023
  • MEDI JECT CORP /MN/Aug 21, 1996 to Mar 14, 20013

Timeline

  1. May 24, 20228-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale40
  2. Apr 13, 20228-K Entered a material agreement; Bylaws or fiscal year changed41
  3. Mar 7, 20228-K Regulation FD disclosure42
  4. Mar 3, 20228-K Results of operations43
  5. Jan 12, 20228-K Regulation FD disclosure44
  6. Jan 11, 20228-K Regulation FD disclosure45
  7. Dec 16, 20218-K Entered a material agreement; Regulation FD disclosure46
  8. Nov 4, 20218-K Results of operations47
  9. Nov 2, 20218-K Entered a material agreement; Ended a material agreement; New debt or obligation48
  10. Oct 28, 20218-K Executive or director change49
  11. Oct 18, 20218-K Other events50
  12. Mar 11, 2016New chief executive Robert F. Apple becomes CEO11
  13. Jun 25, 2014New chief executive Eamonn P. Hobbs becomes CEO12
  14. Oct 21, 2008New chief executive Paul K. Wotton becomes CEO13
  15. Jan 30, 2006New chief executive Jack E. Stover becomes CEO14

Calendar

When it reported results

  1. Mar 3, 2022Reported quarterly or annual results43
  2. Nov 4, 2021Reported quarterly or annual results47

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

87 filings to the SEC since October 2021: 2 annual reports, 2 quarterly reports, 11 major events, 20 insider forms, 5 large holders, 47 other. The latest 20:

  1. Feb 10, 2023SC 13G/A EDGAR
  2. Jun 3, 202215-12B EDGAR
  3. May 31, 2022EFFECT EDGAR
  4. May 31, 2022EFFECT EDGAR
  5. May 31, 2022EFFECT EDGAR
  6. May 31, 2022EFFECT EDGAR
  7. May 31, 2022EFFECT EDGAR
  8. May 31, 2022EFFECT EDGAR
  9. May 31, 2022EFFECT EDGAR
  10. May 31, 2022EFFECT EDGAR
  11. May 31, 2022EFFECT EDGAR
  12. May 31, 2022EFFECT EDGAR
  13. May 31, 2022EFFECT EDGAR
  14. May 26, 20224 FORM 4 SUBMISSION EDGAR
  15. May 26, 20224 FORM 4 SUBMISSION EDGAR
  16. May 26, 20224 FORM 4 SUBMISSION EDGAR
  17. May 26, 20224 FORM 4 SUBMISSION EDGAR
  18. May 26, 20224 FORM 4 SUBMISSION EDGAR
  19. May 26, 20224 FORM 4 SUBMISSION EDGAR
  20. May 26, 20224 FORM 4 SUBMISSION EDGAR

The 87 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How ANTARES PHARMA, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARANTARES PHARMA, INC.1
  • CIK0001016169
  • Employer ID (EIN)41-13501921
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • Business address100 Princeton South, Suite 300, Ewing, NJ 086281
  • Phone609-359-30201
  • Shares outstanding170,852,427 as of May 5, 20229
  • Public float$739.4M as of Jun 30, 202155
  • On EDGAR sinceJun 24, 19961
  • Filings1,187 in all: 4 (533), 8-K (191), 10-Q (77), SC 13G/A (49), DEF 14A (26), 3 (25), 10-K (23), SC 13G (22)1
    All 59 form types

    424B3 (17), EFFECT (17), S-8 (14), S-8 POS (14), POS AM (13), CT ORDER (11), S-3 (11), 4/A (9), 10-K/A (7), 10-Q/A (7), PRE 14A (7), S-3/A (7), SC 13D/A (7), 424B5 (6), DEFA14A (6), SC 14D9/A (6), UPLOAD (6), ARS (5), REGDEX (5), CORRESP (4), NT 10-Q (4), PRER14A (4), S-1/A (4), 10-K405 (3), 424B2 (3), 425 (3), 8-K/A (3), SC 13D (3), SC TO-C (3), SC TO-T/A (3), 10-K405/A (2), 8-A12B (2), 8-A12G (2), DEFR14A (2), FWP (2), NT 10-K (2), S-2 (2), SC14D9C (2), 15-12B (1), 25 (1), 25-NSE (1), 424A (1), 424B1 (1), 5 (1), CERTAMX (1), DEFM14A (1), PREM14A (1), REGDEX/A (1), S-1 (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 3, 2022
    Quarterly report (10-Q) May 10, 2022
    Proxy statement (DEF 14A) Apr 27, 2021
    Latest 8-K (8-K) May 24, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
    SEC EDGAROther events
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56